Celgene, Novartis Chastised Over Cancer Drug Claims

Law360, New York (January 25, 2012, 7:59 PM EST) -- The U.S. Food and Drug Administration chastised Celgene Corp. and Novartis AG in letters released Wednesday for distributing potentially misleading claims in marketing materials that could affect doctors' decisions for prescribing the cancer therapies Abraxane and Gleevec.

One FDA letter focused on promotional materials for Novartis' Gleevec that the agency said overstated the effectiveness of the drug. The other note analyzed a white paper praising Celgene's Abraxane that the FDA said inflated Abraxane's efficacy and didn't mention potential risks and side effects that patients could suffer...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.